scPharma snagged $16M for its self-dosed injectables; Insmed suffers a PhII setback for inhaled antibiotic;

> Startup scPharmaceuticals raked in $16 million for its self-dosed injectables in a Series A financing round. Story

> NJ-based Insmed has another setback on its hands with the failure of its Phase II inhaled antibiotic study of Arikayce. But it's going for breakthrough drug designation from the FDA. Story

> Researchers at the U.K.'s University of Warwick have developed a cancer treatment based on the metal iridium which could help shut down tumor cells. More | Abstract

> Aerogen won recognition in China for innovation and leadership for its work in the last two years rolling out its nebulizer products in the country. Article

> The FDA approved Pinnacle Biologics' Optiguide delivery system to treat non-small cell lung and esophageal cancer. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.